Pharmaceutical API Manufacturing Global Market Report 2024

The pharmaceutical API manufacturing market size has grown strongly in recent years. It will grow from $206.95 billion in 2023 to $219.76 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%.The growth in the historical period can be attributed to an increase in research and development (R&D) expenditure in the pharmaceutical sector, a growing preference for outsourcing active pharmaceutical ingredients (APIs), a rise in the prevalence of chronic illnesses, increased healthcare expenditure, a growth in disposable income, an increase in patent expiration, and the implementation of government policies promoting API production.

The pharmaceutical API manufacturing market size is expected to see strong growth in the next few years. It will grow to $279.03 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing aging population, rapid advancements in technology, a rising prevalence of cancer, increasing mergers and acquisitions, and the high potential of emerging economies, all of which will drive growth. Major trends in the forecast period include a focus on expanding production facilities, the use of artificial intelligence (AI), emphasis on greener API manufacturing, and increased investments and focus on the use of QR code labeling.

The increase in the aging population is a significant driver of the pharmaceutical API manufacturing market. With the rise in the aging population, there is a corresponding increase in the demand for pharmaceutical drugs. APIs play a crucial role in these medicines, serving as specialty drugs to address specific diseases. For example, an article shared by the World Health Organization (WHO) in October 2022 revealed that 80% of senior citizens are projected to reside in low- and middle-income nations by 2050. The aging population is growing at a faster rate than in the past, with more individuals over the age of 60 than under five-year-olds projected for 2020. Therefore, the growth of the aging population is a key factor driving the pharmaceutical API manufacturing market.

The surge in chronic conditions is anticipated to drive the pharmaceutical API manufacturing market in the future. Chronic conditions, or chronic diseases, are long-term health conditions that persist for extended periods, often throughout a person's lifetime, and typically cannot be completely cured. The quality, effectiveness, and safety of medications depend significantly on the API used. pharmaceutical API manufacturing plays a crucial role in producing essential medications for managing chronic diseases. For instance, according to the National Library of Medicine in 2023, it is projected that nearly 36% of US adults aged 50 and older will have at least one chronic condition by 2035, with this number expected to rise to almost 48% by 2050. Therefore, the increase in chronic conditions is a driving force for the pharmaceutical API manufacturing market.


Many companies leverage modern technologies such as process control and powder handling to optimize the manufacturing of Active Pharmaceutical Ingredients (API). These technologies include advancements in Lyophilization, a freeze-drying process involving low-temperature dehydration by freezing the product, lowering pressure, and removing the formed ice. For example, Telstar, a company specializing in efficient integrated systems for pharmaceutical and manufacturing processes, introduced LyoGistics Zero - an automatic loading and unloading system for freeze dryers designed for hazardous products. The system utilizes a linear magnetic driving mechanism, eliminating racks and belts to reduce particle generation and enhance hygiene in API manufacturing. Additionally, ILC Dover, a pharmaceutical company, developed the JetBreaker system, a semi-automatic powder handling system that separates powdered media and buffers powders to improve their mixing in a solution.

Key companies in the pharmaceutical API manufacturing market are dedicated to developing innovative solutions such as Apisolex to streamline manufacturing processes and minimize API loss. Apisolex, launched by Lubrizol Life Science (LLS) Health in March 2022, is a novel solubility-enhancing excipient technology addressing solubility challenges. It can significantly enhance solubility, support high drug loading, and optimize manufacturing efficiency by reducing API loss and ensuring efficient encapsulation.

In March 2021, Piramal Pharma Ltd., an India-based healthcare solutions company, acquired Hemmo Pharmaceuticals for $105.8 million. This strategic acquisition is poised to expand PPS’s capacity to offer integrated services globally, providing access to the growing peptide API industry. The deal is expected to augment peptide API manufacturing and development capabilities. Hemmo Pharmaceuticals, based in India, specializes in the development and manufacturing of peptide APIs.

Major companies operating in the pharmaceutical API manufacturing market report are Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories, BASF SE, Sun Pharmaceutical Industries Ltd., Novartis AG, Lupin Ltd., Cipla Inc., Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt. Ltd., Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc., Otsuka Pharmaceutical Co, Ltd., Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical, Sankyo, GlaxoSmithKline (GSK), AstraZeneca, Abbott Laboratories, Vectura Group, Roche Holding AG, Merck & Co, Boehringer Ingelheim, Zentiva, Microgen, Geropharm, Valenta, NovaMedica, Veropharm, Celon Pharma, SynBio, Generium, Skopinpharm, ALMEDIS, Biocad, Farmacol, Polska Grupa Farmaceutyczna, Polpharma, Mylan, BioVectra, Celgene Corporation, Kashiv Pharma, Cambrex, Eli Lilly and Company, Bristol-Myers Squibb Company, Apotex, Gilead Sciences, AbbVie Inc., Hisun USA Inc., AMEGA Biotech, BioMarin Pharmaceutical, Ferring Pharmaceuticals, Tikun Olam Cannbit, Wavelength Pharmaceuticals, SAUDIBIO, Tabuk Pharmaceuticals, Bayer, Adcock Ingram, Johnson & Johnson, Eurolab, Ranbaxy (SA) (Pty) Ltd., Aspen.

North America was the largest region in the pharmaceutical API manufacturing market in 2023. The Middle East is expected to be the fastest-growing region in the global pharmaceutical API manufacturing market share during the forecast period. The regions covered in the pharmaceutical API manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical API manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

pharmaceutical API manufacturing focuses on various therapy areas, including cardiovascular disorders, metabolic disorders, neurological disorders, oncology, musculoskeletal disorders, NSAIDs, and other therapeutic uses. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels. Chemical API and biological API are the primary types used in the production of innovative drugs, generic prescription drugs, and over-the-counter (OTC) drugs.

The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report is one of a series of new reports that provides pharmaceutical active pharmaceutical ingredients (API) manufacturing market statistics, including pharmaceutical active pharmaceutical ingredients (API) manufacturing industry global market size, regional shares, competitors with a pharmaceutical active pharmaceutical ingredient (API) manufacturing market share, detailed pharmaceutical active pharmaceutical ingredients (API) manufacturing market segments, pharmaceutical active pharmaceutical ingredients (API) manufacturing market trends and opportunities, and any further data you may need to thrive in the pharmaceutical active pharmaceutical ingredients (API) manufacturing industry. The pharmaceutical active pharmaceutical ingredients (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pharmaceutical active pharmaceutical ingredients (API) manufacturing market includes tablets, capsules, creams, and injectable sales. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.